Trial Profile
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2020
Price :
$35
*
At a glance
- Drugs Parsaclisib (Primary) ; Uzansertib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 09 Nov 2020 Status changed from active, no longer recruiting to completed.
- 17 Jul 2020 Planned End Date changed from 1 Sep 2020 to 30 Sep 2020.
- 17 Jul 2020 Planned primary completion date changed from 1 Sep 2020 to 30 Sep 2020.